乳房假体相关间变性大细胞淋巴瘤是异质性T细胞疾病,具促肿瘤交互与免疫抑制
该研究通过单细胞RNA测序分析乳房假体相关间变性大细胞淋巴瘤(BIA-ALCL),发现肿瘤细胞异质性显著,起源为CD4+或CD8+记忆T细胞,肿瘤免疫微环境含免疫抑制信号及促肿瘤交互网络,侵袭性疾病呈T细胞排斥。
要点
- BIA-ALCL细胞异质性高,每例患者基因谱独特,标志基因包括BATF3、SERPINS、TNFSFR8和IL2RA。
- 肿瘤起源为CD4+或CD8+记忆T细胞,依据TCR重排及基因表达鉴定。
- 血清肿中IL-13、IL-10、TNF及分泌型PDL1升高,提示免疫抑制微环境。
核心结论
- BIA-ALCL细胞多样,不同分期免疫微环境差异显著,微环境提供免疫抑制信号及促增殖稳态信号。
研究设计与样本
- 采用单细胞RNA测序分析BIA-ALCL样本,未报告样本量。
主要发现
- BIA-ALCL细胞异质性高,每例患者有独特基因谱,标志基因包括BATF3、SERPINS、TNFSFR8和IL2RA。
- 肿瘤起源为CD4+或CD8+记忆T细胞,通过重排TCR及基因表达鉴定。
- 肿瘤免疫微环境含不同髓系簇、树突状细胞和单核细胞,可能支持淋巴瘤细胞。
- 血清肿中IL-13、IL-10、TNF及分泌型PDL1升高,提示免疫抑制微环境。
- 内源性CD8+ T细胞检查点表达高于良性血清肿,且与BIA-ALCL无克隆关系;侵袭性疾病呈T细胞排斥和免疫抑制微环境。
临床怎么用
- 这些发现可能为晚期BIA-ALCL患者提供新的治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T cell lymphoma in women with textured implants. Little is known about the cell of origin (COO) and whether the tumour immune microenvironment (TIME) is critical for BIA-ALCL survival. Single-cell RNA sequencing revealed BIA-ALCL cells were heterogeneous with unique gene profiles per patient and signature genes BATF3, SERPINS, TNFSFR8, and IL2RA. The COO is a CD4+ or CD8+ memory T cell identified through rearranged TCR and gene expression. The BIA-ALCL TIME included distinct myeloid clusters, dendritic cells (DCs), and monocytes, which may support lymphoma cells. Cytokines IL-13, IL-10, TNF and secretory PDL1 were increased in BIA-ALCL seroma, indicating an immunosuppressive TIME. Interactome analysis revealed a complex network among lymphoma cells, dominated by IL-13, IL-10, and TNF members. Endogenous CD8+ T cells exhibit higher checkpoint expression than benign seromas. No clonal relationship exists between BIA-ALCL and endogenous T cells. Tissue-archetype and gene-expression analysis revealed T-cell exclusion and immunosuppressive TIME in invasive disease. In summary, BIA-ALCL cells are diverse with markedly different TIME across stages. The TIME provides immunosuppressive signals to activated/exhausted T cells and homeostatic signals that promote BIA-ALCL proliferation. These new findings may offer novel therapeutic targets for advanced disease patients.
引用
- D'Souza C, Thio N, Zhu R, et al. Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression. Leukemia. 2026. PMID: 42533032. doi:10.1038/s41375-026-03049-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。